DEA Eyes Baxter Lab's Bulk Marihuana Making Machine
Published Date: 3/27/2025
Notice
Summary
Baxter Research Lab wants to grow and make large amounts of marijuana for medical and scientific research. The DEA is reviewing their application and invites other registered manufacturers to share comments or objections by May 27, 2025. If approved, Baxter will supply marijuana ingredients to researchers, helping science move forward without changing any current rules or costs yet.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Baxter applies to supply research marijuana
If you are a DEA-registered researcher or research lab, Baxter Research Lab applied on August 20, 2024 to be registered to manufacture bulk marihuana (code 7360) and tetrahydrocannabinols (code 7370), both Schedule I. If DEA approves the registration, Baxter would manufacture bulk active pharmaceutical ingredients (APIs) for product development and distribute them to DEA-registered researchers. DEA is accepting comments or objections on or before May 27, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-05275, Pesticide Product Registration; Receipt of Applications for New Active Ingredients (January 2025)
The EPA just announced it got new applications to register pesticides with brand-new active ingredients. If you’re a farmer, gardener, or pesticide maker, this means fresh products might be coming your way soon. You’ve got until April 28, 2025, to share your thoughts before the EPA makes any decisions.
Next: 2025-05277, Bulk Manufacturer of Controlled Substances Application: Bulk Manufacturer of Marihuana: Ohana Bio Pharma, LLC
Ohana Bio Pharma, LLC wants to grow and make large amounts of marijuana for medical and scientific research. The DEA is reviewing their application and invites other registered manufacturers or applicants to share their thoughts by May 27, 2025. If approved, Ohana Bio Pharma will help supply researchers with important marijuana ingredients, boosting medical studies without extra costs to the public.